Vaxcyte, Inc. — Director's Dealing 2023

Oct 4, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2023-10-02

Reporting Person: Eydelman Mikhail (SVP, Gen Counsel & Corp Sec)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-10-02	Common Stock	M	20000	$21.41	Acquired	40487	Direct
2023-10-02	Common Stock	S	7992	$49.58	Disposed	32495	Direct
2023-10-02	Common Stock	S	4874	$50.22	Disposed	27621	Direct
2023-10-02	Common Stock	S	7134	$51.44	Disposed	20487	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-10-02	Stock Option (right to buy)	$21.41	M	20000	Acquired	2032-05-08	Common Stock (20000)	Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $48.94 to $49.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $49.94 to $50.675. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $50.97 to $51.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: 1/4 of the shares subject to the option shall vest on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.